173 related articles for article (PubMed ID: 19491903)
1. Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours.
Hussein D; Holt SV; Brookes KE; Klymenko T; Adamski JK; Hogg A; Estlin EJ; Ward T; Dive C; Makin GW
Br J Cancer; 2009 Jul; 101(1):55-63. PubMed ID: 19491903
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice.
Loadman PM; Phillips RM; Lim LE; Bibby MC
Biochem Pharmacol; 2000 Apr; 59(7):831-7. PubMed ID: 10718341
[TBL] [Abstract][Full Text] [Related]
3. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1.
Dehn DL; Winski SL; Ross D
Clin Cancer Res; 2004 May; 10(9):3147-55. PubMed ID: 15131056
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of the pharmacodynamic properties of 2,5-diaziridinyl-3-hydroxymethyl-6-methyl-1,4-benzoquinone.
Ward TH; Danson S; McGown AT; Ranson M; Coe NA; Jayson GC; Cummings J; Hargreaves RH; Butler J
Clin Cancer Res; 2005 Apr; 11(7):2695-701. PubMed ID: 15814651
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity of the bioreductive agent RH1 and its lack of interaction with radiation.
Kim JY; West CM; Valentine H; Ward TH; Patterson AV; Stratford IJ; Roberts SA; Hendry JH
Radiother Oncol; 2004 Mar; 70(3):311-7. PubMed ID: 15064018
[TBL] [Abstract][Full Text] [Related]
6. The anti-tumour compound, RH1, causes mitochondria-mediated apoptosis by activating c-Jun N-terminal kinase.
Park MT; Song MJ; Oh ET; Lee H; Choi BH; Jeong SY; Choi EK; Park HJ
Br J Pharmacol; 2011 Jun; 163(3):567-85. PubMed ID: 21250978
[TBL] [Abstract][Full Text] [Related]
7. The importance of DT-diaphorase and hypoxia in the cytotoxicity of RH1 in human breast and non-small cell lung cancer cell lines.
Kim JY; Patterson AV; Stratford IJ; Hendry JH
Anticancer Drugs; 2004 Jan; 15(1):71-7. PubMed ID: 15090746
[TBL] [Abstract][Full Text] [Related]
8. Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1).
Yan C; Kepa JK; Siegel D; Stratford IJ; Ross D
Mol Pharmacol; 2008 Dec; 74(6):1657-65. PubMed ID: 18794327
[TBL] [Abstract][Full Text] [Related]
9. Effect of NQO1 induction on the antitumor activity of RH1 in human tumors in vitro and in vivo.
Digby T; Leith MK; Thliveris JA; Begleiter A
Cancer Chemother Pharmacol; 2005 Sep; 56(3):307-16. PubMed ID: 15877230
[TBL] [Abstract][Full Text] [Related]
10. Activity profile of the novel aziridinylbenzoquinones MeDZQ and RH1 in human tumour xenografts.
Cummings J; Ritchie A; Butler J; Ward TH; Langdon S
Anticancer Res; 2003; 23(5A):3979-83. PubMed ID: 14666706
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.
Scotlandi K; Perdichizzi S; Manara MC; Serra M; Benini S; Cerisano V; Strammiello R; Mercuri M; Reverter-Branchat G; Faircloth G; D'Incalci M; Picci P
Clin Cancer Res; 2002 Dec; 8(12):3893-903. PubMed ID: 12473605
[TBL] [Abstract][Full Text] [Related]
12. DT-diaphorase: a target for new anticancer drugs.
Danson S; Ward TH; Butler J; Ranson M
Cancer Treat Rev; 2004 Aug; 30(5):437-49. PubMed ID: 15245776
[TBL] [Abstract][Full Text] [Related]
13. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
Winski SL; Hargreaves RH; Butler J; Ross D
Clin Cancer Res; 1998 Dec; 4(12):3083-8. PubMed ID: 9865924
[TBL] [Abstract][Full Text] [Related]
14. Role of NAD(P)H:quinone oxidoreductase (NQO1) in apoptosis induction by aziridinylbenzoquinones RH1 and MeDZQ.
Nemeikaite-Ceniene A; Dringeliene A; Sarlauskas J; Cenas N
Acta Biochim Pol; 2005; 52(4):937-41. PubMed ID: 15940348
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity study with bioreductive benzoquinone alkylating agents: effects on DT-diaphorase-mediated DNA crosslink and strand break formation in relation to mechanisms of cytotoxicity.
Fourie J; Guziec F; Guziec L; Monterrosa C; Fiterman DJ; Begleiter A
Cancer Chemother Pharmacol; 2004 Mar; 53(3):191-203. PubMed ID: 14614574
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of XIAP by AEG35156 in paediatric tumour cells induces apoptosis and sensitises cells to cytotoxic agents.
Holt SV; Brookes KE; Dive C; Makin GW
Oncol Rep; 2011 Apr; 25(4):1177-81. PubMed ID: 21286665
[TBL] [Abstract][Full Text] [Related]
17. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones.
Winski SL; Swann E; Hargreaves RH; Dehn DL; Butler J; Moody CJ; Ross D
Biochem Pharmacol; 2001 Jun; 61(12):1509-16. PubMed ID: 11377380
[TBL] [Abstract][Full Text] [Related]
18. The reductive activation of the antitumor drug RH1 to its semiquinone free radical by NADPH cytochrome P450 reductase and by HCT116 human colon cancer cells.
Hasinoff BB; Begleiter A
Free Radic Res; 2006 Sep; 40(9):974-8. PubMed ID: 17015278
[TBL] [Abstract][Full Text] [Related]
19. Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1.
Danson SJ; Johnson P; Ward TH; Dawson M; Denneny O; Dickinson G; Aarons L; Watson A; Jowle D; Cummings J; Robson L; Halbert G; Dive C; Ranson M
Ann Oncol; 2011 Jul; 22(7):1653-1660. PubMed ID: 21378203
[TBL] [Abstract][Full Text] [Related]
20. RH1 induces cellular damage in an NAD(P)H:quinone oxidoreductase 1-dependent manner: relationship between DNA cross-linking, cell cycle perturbations, and apoptosis.
Dehn DL; Inayat-Hussain SH; Ross D
J Pharmacol Exp Ther; 2005 May; 313(2):771-9. PubMed ID: 15665137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]